Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

7.06USD
25 Jun 2019
Change (% chg)

$-0.34 (-4.59%)
Prev Close
$7.40
Open
$7.43
Day's High
$7.50
Day's Low
$7.00
Volume
1,008,318
Avg. Vol
923,684
52-wk High
$31.10
52-wk Low
$6.96

Strader, Catherine 

Dr. Catherine D. Strader, Ph.D., serves as Independent Director of the Company. Dr. Strader is a partner at Synergy Partners R&D Solutions, a consultancy network co-founded by Dr. Strader in 2014 which advises biotechnology companies on research and development strategies. Prior to co-founding Synergy Partners, Dr. Strader worked for Merck Research Laboratories, as Vice President and Site Head from 2009 to 2011, and as Vice President, External Basic Research from 2007 to 2009. Prior to that, Dr. Strader held leadership positions at Schering-Plough Corporation before Schering-Plough was acquired by Merck in 2009, including Senior Vice President, Science and Technology in 2007, and Chief Scientific Officer from 2006 to 2007. Prior to that, Dr. Strader was Executive Vice President, Discovery Research from 2002 to 2007, and Vice President, CNS, Cardiovascular and Genomics Research from 1995 to 2001 at Schering-Plough Research Institute. Dr. Strader has guided more than 50 compounds through drug discovery and development during her career. Dr. Strader received a B.S. in Chemistry from the University of Virginia and a Ph.D. in Chemistry from the California Institute of Technology, followed by a Howard Hughes postdoctoral fellowship at Duke University. Dr. Strader is the author of more than 150 scientific publications. Dr. Strader’s extensive pharmaceutical research and development experience, combined with her specific knowledge of neuroscience, makes her well positioned to provide advice and guidance to the Company on its research and development programs.

Basic Compensation

Total Annual Compensation, USD 63,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 304,750
Fiscal Year Total, USD 367,750

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

2,016,980

Richard Batycky

--

David Lawrence

999,491

Jane Wasman

1,986,540

Burkhard Blank

1,477,570

Lauren Sabella

1,488,800
As Of  30 Dec 2017